Status:
UNKNOWN
TIL Relation to pCR After Neoadjuvant Therapy in Breast Cancer Patients
Lead Sponsor:
Ain Shams University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Neoadjuvant systemic treatment for breast cancer (used in locally advanced and operable breast cancer) includes anthracycline based chemotherapy (Doxorubicin/Cyclophosphamide) followed by taxanes (wee...
Detailed Description
Neoadjuvant systemic treatment for breast cancer is used in locally advanced and operable breast cancer. Standard neoadjuvant systemic therapy regimens for breast cancer patients include anthracycline...
Eligibility Criteria
Inclusion
- Patients aged 18 years old or more
- Histologically proven invasive breast cancer
- All patients diagnosed with breast cancer except T1N0 and Metastatic breast cancer
- Patients who completed their systemic neoadjuvant therapy
Exclusion
- Second malignancy
- Patients who started but didn't complete neoadjuvant systemic therapy
- Patients who didn't undergo surgery after neoadjuvant systemic therapy
- Pregnant patients
Key Trial Info
Start Date :
July 24 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT05206396
Start Date
July 24 2022
End Date
September 1 2024
Last Update
July 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Ain Shams University
Cairo, Egypt, 20